305 related articles for article (PubMed ID: 22145956)
1. Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia.
Kristensen T; Preiss B; Broesby-Olsen S; Vestergaard H; Friis L; Møller MB
Leuk Lymphoma; 2012 Jul; 53(7):1338-44. PubMed ID: 22145956
[TBL] [Abstract][Full Text] [Related]
2. Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes.
Xie W; Wang SA; Yin CC; Xu J; Li S; Bueso-Ramos CE; Medeiros LJ; Tang G
Exp Mol Pathol; 2019 Jun; 108():131-136. PubMed ID: 31004601
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of c-KIT mutation in systemic mastocytosis associated with acute myeloid leukaemia patients.
Won D; Chi HS; Shim H; Jang S; Park CJ; Lee JH
Leuk Res; 2013 Aug; 37(8):883-8. PubMed ID: 23683787
[TBL] [Abstract][Full Text] [Related]
4. Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts.
Sasaki K; Tsujimoto S; Miyake M; Uchiyama Y; Ikeda J; Yoshitomi M; Shimosato Y; Tokumasu M; Matsuo H; Yoshida K; Ohki K; Kaburagi T; Yamato G; Hara Y; Takeuchi M; Kinoshita A; Tomizawa D; Taga T; Adachi S; Tawa A; Horibe K; Hayashi Y; Matsumoto N; Ito S; Shiba N
Br J Haematol; 2021 Jul; 194(2):414-422. PubMed ID: 34120331
[TBL] [Abstract][Full Text] [Related]
5. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
[TBL] [Abstract][Full Text] [Related]
6. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
[TBL] [Abstract][Full Text] [Related]
7. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.
Fritsche-Polanz R; Fritz M; Huber A; Sotlar K; Sperr WR; Mannhalter C; Födinger M; Valent P
Mol Oncol; 2010 Aug; 4(4):335-46. PubMed ID: 20471335
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits.
Brioschi M; Fischer J; Cairoli R; Rossetti S; Pezzetti L; Nichelatti M; Turrini M; Corlazzoli F; Scarpati B; Morra E; Sacchi N; Beghini A
Neoplasia; 2010 Nov; 12(11):866-76. PubMed ID: 21076613
[TBL] [Abstract][Full Text] [Related]
9. Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22).
Johnson RC; Savage NM; Chiang T; Gotlib JR; Cherry AM; Arber DA; George TI
Am J Clin Pathol; 2013 Oct; 140(4):525-35. PubMed ID: 24045550
[TBL] [Abstract][Full Text] [Related]
10. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
[TBL] [Abstract][Full Text] [Related]
11. Detection of the KIT
Craig JW; Hasserjian RP; Kim AS; Aster JC; Pinkus GS; Hornick JL; Steensma DP; Coleman Lindsley R; DeAngelo DJ; Morgan EA
Mod Pathol; 2020 Jun; 33(6):1135-1145. PubMed ID: 31896808
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y; Kawashima N; Atsuta Y; Sugiura I; Sawa M; Dobashi N; Yokoyama H; Doki N; Tomita A; Kiguchi T; Koh S; Kanamori H; Iriyama N; Kohno A; Moriuchi Y; Asada N; Hirano D; Togitani K; Sakura T; Hagihara M; Tomikawa T; Yokoyama Y; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H
Blood Adv; 2020 Jan; 4(1):66-75. PubMed ID: 31899799
[TBL] [Abstract][Full Text] [Related]
13. Systemic mastocytosis associated with t(8;21) acute myeloid leukemia in a child: detection of the D816A mutation of KIT.
Yabe M; Masukawa A; Kato S; Yabe H; Nakamura N; Matsushita H
Pediatr Blood Cancer; 2012 Dec; 59(7):1313-6. PubMed ID: 22847983
[TBL] [Abstract][Full Text] [Related]
14. D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
Yui S; Kurosawa S; Yamaguchi H; Kanamori H; Ueki T; Uoshima N; Mizuno I; Shono K; Usuki K; Chiba S; Nakamura Y; Yanada M; Kanda J; Tajika K; Gomi S; Fukunaga K; Wakita S; Ryotokuji T; Fukuda T; Inokuchi K
Ann Hematol; 2017 Oct; 96(10):1641-1652. PubMed ID: 28762080
[TBL] [Abstract][Full Text] [Related]
15. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
[TBL] [Abstract][Full Text] [Related]
16. Characterization of bone marrow mast cells in acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1.
Pullarkat ST; Pullarkat V; Lagoo A; Brynes R; Weiss LM; Bedell V; Chen W; Huang Q; Gaal K; Weisenburger DD; Kim YS
Leuk Res; 2013 Nov; 37(11):1572-5. PubMed ID: 24035334
[TBL] [Abstract][Full Text] [Related]
17. Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.
Nick HJ; Kim HG; Chang CW; Harris KW; Reddy V; Klug CA
Blood; 2012 Feb; 119(6):1522-31. PubMed ID: 21937700
[TBL] [Abstract][Full Text] [Related]
18. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis.
Kristensen T; Vestergaard H; Bindslev-Jensen C; Mortz CG; Kjaer HF; Ollert M; Møller MB; Broesby-Olsen S;
Allergy; 2017 Nov; 72(11):1737-1743. PubMed ID: 28432683
[TBL] [Abstract][Full Text] [Related]
20. KIT D816V mutation-positive cell fractions in lesional skin biopsies from adults with systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB
Dermatology; 2013; 226(3):233-7. PubMed ID: 23774045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
